Understand the medicine before the offer
Start with the basics
What peptide care means
Start with the word “peptide”
A peptide links protein building blocks into a short chain. Insulin is one example.
Seeing “peptide” on a product tells you neither its safety nor its legal status.
“Doctor-led” is a claim to check
Ask who will assess you, who decides on treatment and who answers when you have questions. A doctor’s name in a website header does not answer those questions.
Begin by naming the health problem you need help with. Then ask which options fit it, including options that do not involve a medicine.
Is peptide care real?
The exact product matters. As of September 2026, different rules apply to approved medicines, medicines made to order by a pharmacy and chemicals labelled for lab experiments rather than treatment.
Get the medicine’s complete name, along with its form: pill, shot or something else. A broad label like “peptide therapy” leaves too much unanswered.
Know what is being proposed
Medicine and the rules
Approved products have a named use
FDA stands for Food and Drug Administration. This U.S. agency reviews medicines. An FDA approval covers one named product for a particular use. FDA approval explained
Semaglutide and tirzepatide are medicine ingredients used in products for type 2 diabetes or weight management. Type 2 diabetes is a condition that affects how the body controls blood sugar.
As of September 2026, approved semaglutide products include Ozempic, used for type 2 diabetes, and Wegovy, used for weight management. For tirzepatide, the approved products are Mounjaro to treat type 2 diabetes and Zepbound for weight management. FDA approval records
Ask which approved use applies to your health concern.
Compounding meets a different need
Compounding involves making or changing a medicine for an individual patient rather than supplying a drug company’s ready-made product.
The FDA says it may meet a need an approved product cannot, such as leaving out an ingredient a patient is allergic to. FDA compounding guide
As of September 2026, medicines prepared through compounding have no FDA approval. The FDA does not review compounded medicines for safety, quality or how well they work before they are sold. FDA on compounded drugs
As of September 2026, U.S. law allows compounding within rules for the maker, the ingredients and the type of medicine. It does not allow every ingredient.
An ordinary pharmacy’s rules, as of September 2026, include a licensed pharmacist or doctor and a valid prescription that identifies the patient.
The raw ingredient must meet official drug-quality standards if those exist. Under rules current as of September 2026, an ingredient without those standards must be used in an approved drug or included on the FDA’s list of permitted ingredients.
These are part of the rules the pharmacy must meet. Ask it to explain why the exact medicine it offers is allowed, and check its licence using the steps below.
A research label does not mean treatment
BPC-157, ipamorelin and retatrutide are peptide names you may see in an offer. As of September 2026, none has an FDA-approved U.S. medicine for any health problem. FDA product records
Cagrilintide is another peptide with no FDA-approved use, as of September 2026. The FDA also says federal law does not allow pharmacies to make medicines from retatrutide or cagrilintide. FDA on these ingredients
If one of these names appears in an offer for your health problem, ask: “What are you proposing it would treat, and what evidence supports that use?”
In letters reviewed as of September 2026, the FDA warned that a “research use only” label does not excuse marketing unapproved drugs for people. FDA enforcement letter
If weight loss is the reason for your search
GLP-1 is a hormone that signals within the body to help control blood sugar and appetite. Medicines such as semaglutide and tirzepatide are often called GLP-1 drugs.
In the FDA’s national shortage records, neither semaglutide injections nor tirzepatide is listed as in short supply, as of September 2026. FDA shortage update
A national shortage had allowed pharmacies to make copies of those medicines. As of September 2026, they can no longer rely on that shortage to make copies.
A pharmacy may still be able to make a changed version for one patient, under rules current as of September 2026. The person prescribing it must judge that the alteration has a meaningful effect on that patient’s medical need.
Ask: “What change do I need, and why can’t an approved product meet that need?”
A price reduction alone cannot qualify as that important difference. Adding a vitamin does not, by itself, put a medicine outside the rules for copies. FDA copy rules
Make evidence part of the conversation
What the evidence can tell you
Match the evidence to the exact product
Ask what supports the proposed medicine for your health problem. Is it an approved use, a pharmacy-made version or a product still being studied?
FDA guidance current as of September 2026 calls it misleading to say studies in people prove a compounded medicine matches an approved product’s results. FDA evidence-claim guidance
Ask: “What did studies in people find about this exact medicine for my health problem?” Ask what remains unknown.
A report of a problem does not prove the medicine caused it
The FDA explains that reporting a problem does not establish the medicine as its cause. Those reports also cannot tell you how often a problem occurs. FDA report limitations
That makes a useful question for the visit: how does the evidence fit my own health history?